Acumen Pharmaceuticals SEC filings

Filter: All · 8-K · 10-Q · 10-K · Form 4

8-KOct. 30, 2026, 7:06 a.m. ETView on SEC.gov Our explainer
Regulation FD disclosure · Other events · Financial statements and exhibits
AI summary, unreviewedAcumen Pharmaceuticals (ABOS) Phase 2 ALTITUDE-AD Trial of Sabirnetug Misses Primary Endpoint; Company Ceases Development and Explores Strategic Options
10-QOct. 26, 2026, 4:03 p.m. ETView on SEC.gov
8-KOct. 26, 2026, 7:09 a.m. ETView on SEC.gov
Results of operations and financial condition · Regulation FD disclosure · Financial statements and exhibits
AI summary, unreviewedAcumen Pharmaceuticals (ABOS) Q3 2026: Net loss narrows to $25.4 million; cash and securities fall to $78.6 million, runway into early 2027
8-KSept. 16, 2026, 9:26 a.m. ETView on SEC.gov
Regulation FD disclosure · Financial statements and exhibits
10-QAug. 12, 2026, 4:13 p.m. ETView on SEC.gov
8-KAug. 12, 2026, 7:02 a.m. ETView on SEC.gov
Results of operations and financial condition · Regulation FD disclosure · Financial statements and exhibits